Truxima (rituximab) vs Ukoniq (umbralisib)
Truxima (rituximab) vs Ukoniq (umbralisib)
Truxima (rituximab) is a CD20-directed cytolytic antibody used in the treatment of certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. It works by targeting and destroying B cells, which are a type of white blood cell that can become cancerous or cause autoimmune problems. On the other hand, Ukoniq (umbralisib) is a kinase inhibitor used for the treatment of marginal zone lymphoma and follicular lymphoma, and it functions by inhibiting specific proteins that contribute to cancer cell growth and survival. When deciding which medicine is right for an individual, it is crucial to consider the specific type of cancer or condition being treated, as well as the patient's overall health, previous treatments, and potential side effects of each medication. A healthcare provider would assess these factors and the patient's medical history to determine the most appropriate treatment option.
Difference between Truxima and Ukoniq
| Metric | Truxima (rituximab) | Ukoniq (umbralisib) |
|---|---|---|
| Generic name | Rituximab | Umbralisib |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis | Marginal zone lymphoma, follicular lymphoma |
| Mechanism of action | CD20-directed cytolytic antibody | PI3K delta inhibitor |
| Brand names | Truxima, Rituxan, MabThera | Ukoniq |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Infusion reactions, infections, body aches, fatigue, skin rash | Nausea, diarrhea, fatigue, musculoskeletal pain, anemia |
| Contraindications | Severe infections, hepatitis B reactivation, severe cardiac disease | None known specifically; caution in patients with severe hepatic impairment or severe infection |
| Drug class | Monoclonal antibody | Small molecule kinase inhibitor |
| Manufacturer | Genentech (a member of the Roche Group), Biogen | TG Therapeutics, Inc. |
Efficacy
Truxima (rituximab) Efficacy in Lymphoma
Truxima, a biosimilar to the original rituximab product, is a monoclonal antibody that targets the CD20 antigen on the surface of pre-B and mature B lymphocytes. In the treatment of non-Hodgkin's lymphoma (NHL), Truxima has demonstrated efficacy in inducing remission and improving survival rates. It is particularly effective in B-cell NHL, including follicular lymphoma and diffuse large B-cell lymphoma. Clinical trials have shown that when combined with chemotherapy, Truxima can significantly prolong progression-free survival compared to chemotherapy alone. Additionally, maintenance therapy with Truxima has been associated with improved overall survival in patients with follicular lymphoma.
For chronic lymphocytic leukemia (CLL), which is a type of lymphoma, Truxima has also shown benefits. It is commonly used in combination with chemotherapy and has been found to increase the time to disease progression and overall survival. The efficacy of Truxima in CLL was further established through randomized clinical trials, which demonstrated improved treatment outcomes compared to chemotherapy alone.
Ukoniq (umbralisib) Efficacy in Lymphoma
Ukoniq (umbralisib) is a novel medication that inhibits both PI3K-delta and CK1-epsilon, which are enzymes involved in the growth and survival of cancer cells. It has been approved for the treatment of marginal zone lymphoma (MZL) and follicular lymphoma after at least one prior anti-CD20-based regimen. In clinical studies, umbralisib has shown promising efficacy in patients with relapsed or refractory MZL and follicular lymphoma, with a considerable proportion of patients achieving partial or complete responses to the treatment.
In a pivotal phase 2 trial, umbralisib demonstrated an overall response rate of 55% in patients with MZL and 45% in those with follicular lymphoma. The duration of response also supported the drug's efficacy, with a median duration of response that was not reached in the MZL cohort and was 11.1 months in the follicular lymphoma cohort at the time of data cut-off. These results indicate that Ukoniq holds significant potential as a treatment option for patients with these types of lymphoma who have exhausted other therapies.
Regulatory Agency Approvals
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Ukoniq
-
Food and Drug Administration (FDA), USA
Access Truxima or Ukoniq today
If Truxima or Ukoniq are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us